Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Purpose

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Condition

  • Complex Regional Pain Syndrome

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Upper and/or lower extremity CRPS - On stable treatment for 1 month - CRPS for at least 1 year - Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria

  • Any known allergy to naltrexone or naloxone - Use of prescription opioid analgesics or illegal opioid use - Current or planned pregnancy.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LDN 		Naltrexone HCL, 4.5 mg, Once a day.
  • Drug: LDN
Placebo Comparator
Placebo 		Sugar pill
  • Drug: Placebo
    Sugar pill

Recruiting Locations

Stanford University
Palo Alto 5380748, California 5332921 94304
Contact:
Birute Gedrimaite
650-497-0485
birute@stanford.edu

More Details

Status
Recruiting
Sponsor
Stanford University

Study Contact

Birute Gedrimaite
(650) 497-0485
birute@stanford.edu